Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer

Biomarkers

Volumn 16, Issue 4, 2011, Pages 311-320

  Petrović, Marina ^a   Baskić, Dejan ^b,c   Banković, Dragić ^d   Ilić, Nevenka ^b  

^a Clinical Center   (Serbia)

^b Public Health Institute   (Serbia)

^c Medical Faculty   (Serbia)

^d UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

chemotherapy; lung cancer; neuroendocrine markers; Nonmicrocellular; survival; therapeutic response

Indexed keywords

CHROMOGRANIN A; CISPLATIN; DOCETAXEL; NEURON SPECIFIC ENOLASE; PACLITAXEL; SYNAPTOPHYSIN;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHEMOSENSITIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NERVE CELL DIFFERENTIATION; NEUROENDOCRINE DIFFERENTIATION; NEUROENDOCRINE SYSTEM; PREDICTOR VARIABLE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CHROMOGRANIN A; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE CELLS; NEUROENDOCRINE TUMORS; PACLITAXEL; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; SYNAPTOPHYSIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79957528306     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.560281     Document Type: Article

References (57)

1. Abbona G, Papotti M, Viberti L, Macri L, Stella A, Bussolati G. (1998). Chromogranin A gene expression in non-small cell lung carcinomas. J Pathol 186:151-156. (Pubitemid 28467824)
2. Axiotis CA. (2002). The neuroendocrine lung. In: Li Volsi V, Asa SL, editors. Endocrine pathology. New York: Churchill Livingstone, 261-96.
3. Baldi A, Groger AM, Esposito V, Di Marino MP, Ferrara N, Baldi F. (2000). Neuroendocrine differentiation in non-small cell lung carcinomas. In Vivo 14:109-114. (Pubitemid 30192117)
4. Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ, The H. (1989). Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 7:1614-1620. (Pubitemid 19272830)
5. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci usa 98:13790-13795. (Pubitemid 33115977)
6. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. (2001). The new World Health Organization classification of lung tumours. Eur Respir J 18:1059-1068. (Pubitemid 34092881)
7. Brundage MD, Davies D, Mackillop WJ. (2002). Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122:1037-1057.
8. Carey FA, Save VE. (1997). Neuroendocrine differentiation in lung cancer. J Pathol 182:9-10.
9. Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, Fernandez-Vasalo G, Abad A, Barnadas A. (1993). Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 10:209-219. (Pubitemid 24033206)
10. Carnaghi C, Rimassa L, Garassino I, Santoro A. (2001). Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. Ann Oncol 12 Suppl 2:S119-S123. (Pubitemid 33069700)
11. Corrin B. (2000). Pathology of the lungs. London, UK: Churchill Livingstone.
12. Ferrigno D, Buccheri G, Giordano C. (2003). Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer 41:311-320. (Pubitemid 36970187)
13. Gajra A, Tatum AH, Newman N, Gamble GP, Lichtenstein S, Rooney MT, Graziano SL. (2002). The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer 36:159-165. (Pubitemid 34302892)
14. Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, Park JG. (1988). Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 48:4078-4082.
15. González-Aragoneses F, Moreno-Mata N, Cebollero-Presmanes M, Garcí-Yuste M, Cañizares-Carretero MA, Molins-López- Rodó L, Quevedo-Losada S, Torres-Lanzas J, Alvarez-Fernández E; Spanish Multicenter Study of Neuroendocrine Tumours of the Lung of the Spanish Society of Pneumonology, ThoracicSurgery (EMETNESEPAR). (2007). Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. Cancer 110:1776-1781. (Pubitemid 47557302)
16. Gosney JR, Gosney MA, Lye M, Butt SA. (1995). Reliability of commercially available immunocytochemical markers for identification of neuroendocrine differentiation in bronchoscopic biopsies of bronchial carcinoma. Thorax 50:116-120.
17. Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, Sugarbaker D, Skarin AT, Kreisman H, Green MR. (1998). Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 21:203-211. (Pubitemid 28491368)
18. Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, Gullo JJ, DiFino SM, Scalzo AJ. (1989). The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J Clin Oncol 7:1398-1406. (Pubitemid 19245109)
19. Graziano SL, Tatum A, Herndon JE 2nd, Box J, Memoli V, Green MR, Kern JA. (2001). Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III nonsmall cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33:115-123. (Pubitemid 32717081)
20. Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, Gamble GP, Coleman MJ, Barmada S, O'Lear S. (1994). The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res 54:2908-2913. (Pubitemid 24187771)
21. Hage R, Elbers HRJ, De la Riviere AB, Van Den Bosch JMM. (1998). Neural cell adhesion molecule. Prognosis in 889 patients with resected non-small cell lung cancer. Chest 14:1316-20. (Pubitemid 28527405)
22. Harada M, Yokose T, Yoshida J, Nishiwaki Y, Nagai K. (2002). Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung. Lung Cancer 38:177-184. (Pubitemid 35157755)
23. Hiroshima K, Iyoda A, Shibuya K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. (2002). Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg 73:1732-1735. (Pubitemid 34596708)
24. Howe MC, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS. (2005). Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 46:195-201. (Pubitemid 40293018)
25. Ionescu DN, Treaba D, Gilks CB, Leung S, Renouf D, Laskin J, Wood-Baker R, Gown AM. (2007). Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic significance. Am J Surg Pathol 31:26-32. (Pubitemid 46036899)
26. Ishikawa H, Satoh H, Sekizawa K. (2004). Is NSE truly a useful marker in NSCLC? Lung Cancer 44:267; author reply 269.
27. Jacot W, Quantin X, Boher JM, Andre F, Moreau L, Gainet M, Depierre A, Quoix E, Chevalier TL, Pujol JL; Association d'Enseignement et de Recherche des Internes en Oncologie. (2001). Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. Br J Cancer 84:903-909. (Pubitemid 32385832)
28. Jeanmart M, Lantuejoul S, Fievet F, Moro D, Sturm N, Brambilla C, Brambilla E. (2003). Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res 9:2195-2203. (Pubitemid 36687643)
29. Kibbelaar RE, Moolenaar KE, Michalides RJ, Van Bodegom PC, Vanderschueren RG, Wagenaar SS, Dingemans KP, Bitter- Suermann D, Dalesio O, Van Zandwijk N. (1991). Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer 27:431-435.
30. Kiriakogiani-Psaropoulou P, Malamou-Mitsi V, Martinopoulou U, Legaki S, Tamvakis N, Vrettou E, Fountzilas G, Skarlos D, Kosmidis P, Pavlidis N. (1994). The value of neuroendocrine markers in nonsmall cell lung cancer: a comparative immunohistopathologic study. Lung Cancer 11:353-364.
31. Kwa HB, Michalides RJ, Dijkman JH, Mooi WJ. (1996a). The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. Lung Cancer 14:207-217. (Pubitemid 26191583)
32. Kwa HB, Verheijen MG, Litvinov SV, Dijkman JH, Mooi WJ, Van Krieken JH. (1996b). Prognostic factors in resected non-small cell lung cancer: an immunohistochemical study of 39 cases. Lung Cancer 16:35-45.
33. Leung AS-Y, Cooper K, Leung FJW-M. (1999). Manual of diagnostic antibodies for immunohistology. London UK: Greenwich Medical Media.
34. Linnoila RI, Piantadosi S, Ruckdeschel JC. (1994). Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 106:367S-371S. (Pubitemid 24370977)
35. Lyda MH, Weiss LM. (2000). Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 31:980-987.
36. Maeda T, Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, Takigawa N, Hiraki A, Katayama H, Harada M. (2000). Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Clin Oncol 30:534-541. (Pubitemid 32149375)
37. Mountain CF. (1997). Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717. (Pubitemid 27260107)
38. Pelosi G, Pasini F, Sonzogni A, Maffini F, Maisonneuve P, Iannucci A, Terzi A, De Manzoni G, Bresaola E, Viale G. (2003). Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer 97:2487-2497. (Pubitemid 36542488)
39. Petersen I. (1999). [Rudolf-Virchow Prize 1999. Genetics of respiratory tract carcinomas: correlation of genotype and phenotype]. Verh Dtsch Ges Pathol 83:195-204.
40. Petroviæ M, Tomic I, Ilic S. (2007). [Neuroendocrine differentiation as a survival prognostic factor in advanced non-small cell lung cancer]. Vojnosanit Pregl 64:525-529.
41. Pujol JL, Boher JM, Grenier J, Quantin X. (2001). Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31:221-231. (Pubitemid 32109238)
42. Pujol JL, Simony J, Demoly P, Charpentier R, Laurent JC, DaurèsJP, Lehmann M, Guyot V, Godard P, Michel FB. (1993). Neural cell adhesion molecule and prognosis of surgically resected lung cancer. Am Rev Respir Dis 148:1071-1075. (Pubitemid 23301233)
43. Satoh H, Ishikawa H, Kurishima K, Yamashita YT, Ohtsuka M, Sekizawa K. (2002). Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncol Rep 9:581-583.
44. Schleusener JT, Tazelaar HD, Jung SH, Cha SS, Cera PJ, Myers JL, Creagan ET, Goldberg RM, Marschke RF Jr. (1996). Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer 77:1284-1291. (Pubitemid 26102325)
45. Segawa Y, Takata S, Fujii M, Oze I, Fujiwara Y, Kato Y, Ogino A, Komori E, Sawada S, Yamashita M, Nishimura R, Teramoto N, Takashima S. (2009). Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol 135:1055-1059.
46. Senden N, Linnoila I, Timmer E, van de Velde H, Roebroek A, Van de Ven W, Broers J, Ramaekers F. (1997). Neuroendocrine-specific protein (NSP)-reticulons as independent markers for non-small cell lung cancer with neuroendocrine differentiation. An in vitro histochemical study. Histochem Cell Biol 108:155-165. (Pubitemid 27362342)
47. Skov BG, Sørensen JB, Hirsch FR, Larsson LI, Hansen HH. (1991). Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 2:355-360.
48. Spira A, Ettinger DS. (2004). Multidisciplinary management of lung cancer. N Engl J Med 350:379-392. (Pubitemid 38101633)
49. Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM. (1991). Neuroendocrine differentiation and clinical behaviour in nonsmall cell lung tumours. Br J Cancer 64:333-338.
50. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216. (Pubitemid 30099779)
51. Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. (2008). Predictive and prognostic significance of neuron-specific enolase (NSE) in nonsmall cell lung cancer. Anticancer Res 28:507-513. (Pubitemid 351362861)
52. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. (1999). Hystological typing of lung and pleural tumours. Berlin: Springer Verlag.
53. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H, Doppman J. (1991). Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 15:529-553.
54. Travis WD. (2009). Lung tumours with neuroendocrine differentiation. Eur J Cancer 45 Suppl 1:251-266.
55. Wertzel H, Grahmann PR, Bansbach S, Lange W, Hasse J, Böhm N. (1997). Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression. Eur j Cardiothorac Surg 12:698-702. (Pubitemid 28035531)
56. World Health Organisation. (1999). International histological classification of tumours. Histological typing of lung and pleural tumours, 3rd edn. Geneva: WHO.
57. Zhu CQ, Shih W, Ling CH, Tsao MS. (2006). Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59:790-800. (Pubitemid 44211740)